William Blair Issues Pessimistic Outlook for TENX Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Analysts at William Blair lowered their Q2 2025 earnings per share (EPS) estimates for Tenax Therapeutics in a note issued to investors on Wednesday, May 14th. William Blair analyst M. Phipps now expects that the specialty pharmaceutical company will earn ($0.24) per share for the quarter, down from their previous estimate of ($0.22). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. William Blair also issued estimates for Tenax Therapeutics’ Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.02) EPS, Q1 2026 earnings at ($0.26) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.05) EPS and FY2027 earnings at ($1.15) EPS.

TENX has been the subject of several other research reports. StockNews.com started coverage on shares of Tenax Therapeutics in a research report on Friday, May 16th. They issued a “sell” rating for the company. Leerink Partners set a $20.00 price target on shares of Tenax Therapeutics in a research report on Monday, March 10th. Finally, Guggenheim reissued a “buy” rating and issued a $15.00 price target on shares of Tenax Therapeutics in a research report on Thursday, May 15th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $17.50.

Tenax Therapeutics Price Performance

Shares of TENX stock opened at $6.00 on Monday. The stock has a market cap of $24.89 million, a P/E ratio of -2.42 and a beta of 1.92. Tenax Therapeutics has a one year low of $2.77 and a one year high of $7.89. The stock has a fifty day moving average price of $5.85 and a 200 day moving average price of $5.93.

Tenax Therapeutics (NASDAQ:TENX) last issued its earnings results on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC bought a new position in shares of Tenax Therapeutics during the fourth quarter valued at $1,026,000. ADAR1 Capital Management LLC lifted its holdings in shares of Tenax Therapeutics by 98.1% during the first quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock valued at $450,000 after acquiring an additional 34,048 shares during the period. Millennium Management LLC bought a new position in shares of Tenax Therapeutics during the fourth quarter valued at $166,000. Geode Capital Management LLC lifted its holdings in shares of Tenax Therapeutics by 32.4% during the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after acquiring an additional 5,964 shares during the period. Finally, Two Sigma Investments LP bought a new position in shares of Tenax Therapeutics during the fourth quarter valued at $84,000. 1.67% of the stock is owned by institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.